Spruce BiosciencesSPRB
Market Cap: $18.7M
About: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Employees: 22
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
113% more call options, than puts
Call options by funds: $66K | Put options by funds: $31K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
3.45% less ownership
Funds ownership: 43.72% [Q1] → 40.27% (-3.45%) [Q2]
26% less funds holding
Funds holding: 50 [Q1] → 37 (-13) [Q2]
39% less capital invested
Capital invested by funds: $14.1M [Q1] → $8.6M (-$5.54M) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
RBC Capital Gregory Renza 55% 1-year accuracy 36 / 66 met price target | 343%upside $2 | Sector Perform Reiterated | 13 Aug 2024 |
Financial journalist opinion
Based on 37 articles about SPRB published over the past 30 days